Literature DB >> 8580719

Disruption of the cytoskeleton in Alzheimer's disease.

V M Lee1.   

Abstract

Paired helical filaments (PHFs) in Alzheimer's disease are formed from hyperphosphorylated brain tau known as PHF-tau. Many sites of phosphorylation that were thought to be present only in PHF-tau are now known to be normal phosphate acceptor sites in both fetal and rapidly processed adult brain tau. The rapid dephosphorylation of normal brain tau by protein phosphatases 2A and 2B provides an explanation for the apparent absence of phosphates at these sites in the normal adult brain tau obtained postmortem. Although the functional significance of each of these normal phosphate acceptor sites is unknown at this time, emerging evidence suggests that the binding of tau to microtubules is regulated by the simultaneous phosphorylation and dephosphorylation of tau at multiple sites.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8580719     DOI: 10.1016/0959-4388(95)80073-5

Source DB:  PubMed          Journal:  Curr Opin Neurobiol        ISSN: 0959-4388            Impact factor:   6.627


  10 in total

1.  14-3-3 proteins in neurological disorders.

Authors:  Molly Foote; Yi Zhou
Journal:  Int J Biochem Mol Biol       Date:  2012-05-18

2.  A critical assessment of the information processing capabilities of neuronal microtubules using coherent excitations.

Authors:  Travis John Adrian Craddock; Jack A Tuszynski
Journal:  J Biol Phys       Date:  2010-01       Impact factor: 1.365

Review 3.  The role of glycoproteins in neural development function, and disease.

Authors:  K C Breen; C M Coughlan; F D Hayes
Journal:  Mol Neurobiol       Date:  1998-04       Impact factor: 5.590

Review 4.  Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling.

Authors:  V Janssens; J Goris
Journal:  Biochem J       Date:  2001-02-01       Impact factor: 3.857

Review 5.  Interactions between beta-amyloid and central cholinergic neurons: implications for Alzheimer's disease.

Authors:  Satyabrata Kar; Stephen P M Slowikowski; David Westaway; Howard T J Mount
Journal:  J Psychiatry Neurosci       Date:  2004-11       Impact factor: 6.186

6.  Update on the pharmacological treatment of Alzheimer's disease.

Authors:  Fadi Massoud; Serge Gauthier
Journal:  Curr Neuropharmacol       Date:  2010-03       Impact factor: 7.363

7.  Epigallocatechin-3-gallate modulates Tau Post-translational modifications and cytoskeletal network.

Authors:  Shweta Kishor Sonawane; Subashchandrabose Chinnathambi
Journal:  Oncotarget       Date:  2021-05-25

Review 8.  Tau-Induced Pathology in Epilepsy and Dementia: Notions from Patients and Animal Models.

Authors:  Marina P Sánchez; Ana M García-Cabrero; Gentzane Sánchez-Elexpuru; Daniel F Burgos; José M Serratosa
Journal:  Int J Mol Sci       Date:  2018-04-05       Impact factor: 5.923

9.  GJA1 (connexin43) is a key regulator of Alzheimer's disease pathogenesis.

Authors:  Yuji Kajiwara; Erming Wang; Minghui Wang; Wun Chey Sin; Kristen J Brennand; Eric Schadt; Christian C Naus; Joseph Buxbaum; Bin Zhang
Journal:  Acta Neuropathol Commun       Date:  2018-12-21       Impact factor: 7.801

Review 10.  Neuroprotective function of 14-3-3 proteins in neurodegeneration.

Authors:  Tadayuki Shimada; Alyson E Fournier; Kanato Yamagata
Journal:  Biomed Res Int       Date:  2013-12-02       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.